HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Natural, safe, seaweed-based hair dyes?

This article was originally published in The Rose Sheet

Executive Summary

Researchers at the University of Leeds are launching a project to develop safe, natural hair dyes from compounds extracted from seaweed found around the Shetland Islands, according to a July 23 release. Islands off northern coast of Scotland are rich in diverse species of seaweed that researchers believe could yield a range of colors including blond, brown, red and black and represent an attractive alternative to synthetic ingredients used in existing hair dyes, which have been linked to allergic reactions and more serious long-term health effects, researchers note. Seaweed extracts also may be used to formulate safer and "greener" cosmetics, including hair treatments and skin care, release notes. "Seaweed is especially suited to being used in cosmetics because it has evolved very clever techniques to protect itself from weathering. And cosmetics are all about protection from aging and the elements," says Dr. Richard Blackburn, one of the project's leaders and a senior lecturer in coloration technology in UL's Center for Technical Textiles. L'Oreal brand The Body Shop has contributed funding to the more than $800,000 project, according to the release

You may also be interested in...



Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016317

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel